IRIS
Cento, Valeria
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.317
AS - Asia 2.778
EU - Europa 917
SA - Sud America 599
AF - Africa 138
OC - Oceania 1
Totale 8.750
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.227
SG - Singapore 1.679
CN - Cina 516
BR - Brasile 486
VN - Vietnam 272
FI - Finlandia 186
IT - Italia 149
IE - Irlanda 144
DE - Germania 98
FR - Francia 61
GB - Regno Unito 60
NG - Nigeria 59
SE - Svezia 55
HK - Hong Kong 53
IN - India 45
AR - Argentina 41
NL - Olanda 41
BD - Bangladesh 37
CA - Canada 33
MX - Messico 27
ZA - Sudafrica 26
EC - Ecuador 22
IQ - Iraq 21
JP - Giappone 20
PL - Polonia 19
RU - Federazione Russa 19
TR - Turchia 19
ID - Indonesia 17
BE - Belgio 16
ET - Etiopia 15
CL - Cile 13
ES - Italia 12
SA - Arabia Saudita 12
CO - Colombia 11
UA - Ucraina 11
MY - Malesia 10
VE - Venezuela 10
MA - Marocco 9
PA - Panama 9
PH - Filippine 8
PK - Pakistan 8
PY - Paraguay 8
KE - Kenya 7
DO - Repubblica Dominicana 6
GR - Grecia 6
JO - Giordania 6
AT - Austria 5
AZ - Azerbaigian 5
BH - Bahrain 5
DZ - Algeria 5
EG - Egitto 5
KZ - Kazakistan 5
AM - Armenia 4
BG - Bulgaria 4
CM - Camerun 4
CR - Costa Rica 4
CZ - Repubblica Ceca 4
IL - Israele 4
LV - Lettonia 4
NP - Nepal 4
PE - Perù 4
TW - Taiwan 4
UZ - Uzbekistan 4
AE - Emirati Arabi Uniti 3
BO - Bolivia 3
DK - Danimarca 3
EE - Estonia 3
JM - Giamaica 3
KG - Kirghizistan 3
MD - Moldavia 3
PT - Portogallo 3
RO - Romania 3
GE - Georgia 2
GT - Guatemala 2
HN - Honduras 2
HR - Croazia 2
IR - Iran 2
PS - Palestinian Territory 2
SN - Senegal 2
TH - Thailandia 2
TN - Tunisia 2
AL - Albania 1
AO - Angola 1
BA - Bosnia-Erzegovina 1
BF - Burkina Faso 1
BN - Brunei Darussalam 1
CH - Svizzera 1
CI - Costa d'Avorio 1
KW - Kuwait 1
KY - Cayman, isole 1
LB - Libano 1
LU - Lussemburgo 1
MF - Saint Martin 1
MU - Mauritius 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
OM - Oman 1
QA - Qatar 1
SK - Slovacchia (Repubblica Slovacca) 1
SV - El Salvador 1
Totale 8.747
Salva come PNG Salva come JPEG
Città #
Dallas 878
Singapore 666
Ashburn 555
San Jose 484
Chandler 399
The Dalles 279
Shanghai 219
Helsinki 185
Dublin 144
Boardman 140
New York 137
Beijing 97
Los Angeles 80
Ho Chi Minh City 78
Lawrence 72
Princeton 72
Hanoi 68
Benin City 59
Santa Clara 52
Hong Kong 51
Council Bluffs 46
Paris 36
São Paulo 35
Amsterdam 31
Milan 28
Bari 24
Buffalo 23
London 22
Seattle 21
Falkenstein 20
Da Nang 18
Pune 16
Rome 16
Chicago 15
Haiphong 15
Johannesburg 15
Rio de Janeiro 15
Tokyo 15
Brussels 14
Phoenix 14
Warsaw 14
Atlanta 13
Munich 13
Wilmington 13
Brooklyn 12
Guayaquil 12
Orem 12
San Francisco 12
Addis Ababa 11
Boston 11
Ribeirão Preto 11
Montreal 10
Belo Horizonte 9
Brasília 9
Campinas 9
Stockholm 9
Assago 8
Baghdad 8
Charlotte 8
Naples 8
Ankara 7
Ann Arbor 7
Cagliari 7
Chennai 7
Curitiba 7
Frankfurt am Main 7
Guarulhos 7
Mexico City 7
Moscow 7
Toronto 7
Alessandria 6
Bắc Ninh 6
Denver 6
Fortaleza 6
Las Vegas 6
Pasadena 6
Quito 6
Salvador 6
Sorocaba 6
Amman 5
Baku 5
Caracas 5
Casablanca 5
Dhaka 5
Guarujá 5
Houston 5
Istanbul 5
Jeddah 5
Jundiaí 5
Nairobi 5
Poplar 5
Santiago 5
São Gonçalo 5
Thái Nguyên 5
Aracaju 4
Durban 4
Kuala Lumpur 4
Lahore 4
Manama 4
Mumbai 4
Totale 5.589
Salva come PNG Salva come JPEG
Nome #
What is the impact of anti-enterococcal empirical therapy on survival of patients with enterococcal bloodstream infections? 433
Endonasal filters for the prevention and control of respiratory allergy and infections. A multi-stakeholder assessment 346
Beyond the distance between juridic and scientific decision-making process: An evidence-based prediction algorithm for professional liability assessment in healthcare-associated infections 111
Real life experiences in HCV management in 2018 105
Genetic diversity of human papillomavirus type 16 E6, E7, and L1 genes in Italian women with different grades of cervical lesions 94
HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels 91
Safety and effectiveness of fifth generation cephalosporins for the treatment of methicillin-resistant staphylococcus aureus bloodstream infections: a narrative review exploring past, present, and future 91
Characterization of drug resistance mutations in naïve and ART-treated patients infected with HIV-1 in Yaounde, Cameroon 90
Treatment of Hepatitis C virus infection in Italy: A consensus report from an expert panel 89
Results of the RENAISSANCE Study: REsponse to BNT162b2 COVID-19 vacciNe-short- And long-term Immune reSponSe evAluatioN in health Care workErs 88
Characterization of drug-resistance mutations in HBV D-genotype chronically infected patients, naïve to antiviral drugs 87
Resistance analysis and treatment outcomes in hepatitis C virus genotype 3‐infected patients within the Italian network VIRONET‐C 87
SARS-CoV-2 RNA in plasma samples of COVID-19 affected individuals: a cross-sectional proof-of-concept study 83
A boceprevir failure in a patient infected with HCV genotype 1g: importance and limitations of virus genotyping prior to HCV protease-inhibitor-based therapy 80
The European Prevalence of Resistance Associated Substitutions among Direct Acting Antiviral Failures 79
Rapid prediction of sustained virological response in patients chronically infected with HCV by evaluation of RNA decay 48h after the start of treatment with pegylated interferon and ribavirin 78
Back to the future (of common respiratory viruses) 78
Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals 77
CMV seroprevalence and coronary CMV-DNA detection in immunocompetent patients with heart diseases 74
Consequences of inaccurate hepatitis C virus genotyping on the costs of prescription of direct antiviral agents in an Italian district 74
Biotech innovations in the prevention of respiratory infectious diseases 74
Anti-HBV treatment induces novel reverse transcriptase mutations with reflective effect on HBV S antigen 73
Genetic Determinants in a Critical Domain of NS5A Correlate with Hepatocellular Carcinoma in Cirrhotic Patients Infected with HCV Genotype 1b 70
CLINICAL RELEVANCE OF NEXT GENERATION SEQUENCING ON BASELINE DETECTION OF MINORITY RESISTANCE ASSOCIATED VARIANTS IN HCV-1 PATIENTS TREATED WITH PROTEASE INHIBITORS 70
Pomegranate Extract Affects Gut Biofilm Forming Bacteria and Promotes Intestinal Mucosal Healing Regulating the Crosstalk between Epithelial Cells and Intestinal Fibroblasts 70
Sex differences in electrolyte imbalances caused by SARS-CoV-2: A cross-sectional study 69
Kinetics of hepatitis C virus RNA decay, quasispecies evolution and risk of virological failure during telaprevir-based triple therapy in clinical practice 69
Effectiveness of infection-containment measures on SARS-CoV-2 seroprevalence and circulation from May to July 2020, in Milan, Italy 68
Nucleotide polymorphisms in the 5'-UTR region of HCV can affect the ability of two widely used assays to assign an HCV genotype 68
Quantification of 1,3-β-d-glucan by Wako β-glucan assay for rapid exclusion of invasive fungal infections in critical patients: A diagnostic test accuracy study 68
Novel HBsAg markers tightly correlate with occult HBV infection and strongly affect HBsAg detection 68
Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy 67
CLINICAL RELEVANCE OF ACCURATE HCV GENOTYPE AND SUBTYPE ASSIGNMENT BY NS3/NS5A/NS5B DIRECT SEQUENCING IN THE ERA OF NEW DIRECT ACTING ANTIVIRAL AGENTS 67
Detection and quantification of SARS-CoV-2 by droplet digital PCR in real-time PCR negative nasopharyngeal swabs from suspected COVID-19 patients 66
Hepatitis C virus RNA levels at week-2 of telaprevir/boceprevir administration are predictive of virological outcome 66
May some HCV genotype 1 patients still benefit from dual therapy? The role of very early HCV kinetics 66
Performance evaluation of an in-house human immunodeficiency virus type-1 protease-reverse transcriptase genotyping assay in Cameroon 66
BIPHASIC KINETICS OF HCV-RNA DECAY IS ACCOMPANIED BY AN EVEN FASTER AMINOTRANSFERASES NORMALIZATION IN ALL-DAA TREATED CIRRHOTIC PATIENTS: A DIFFERENT SCENARIO FROM INTERFERON-BASED THERAPIES 65
Detecting Hepatitis B Viral Amino Acid Sequence Mutations in Occult Hepatitis B Infections via Bayesian Partition Model 64
Hepatitis C virus genetic variability and the presence of NS5B resistance-associated mutations as natural polymorphisms in selected genotypes could affect the response to NS5B inhibitors 64
Genomic epidemiology of SARS-CoV-2 reveals multiple lineages and early spread of SARS-CoV-2 infections in Lombardy, Italy 64
Drug resistance among drug-naive and first-line antiretroviral treatment-failing children in Cameroon 64
In vivo acquisition and risk of inter-species spread of bla KPC-3-plasmid from Klebsiella pneumoniae to Serratia marcescens in the lower respiratory tract 63
Short article: Retreatment of chronic hepatitis C virus infection after unsuccessful therapy with all-oral direct-acting antiviral regimens: a real-life experience 63
Optimal efficacy of interferon-free HCV retreatment after protease inhibitor failure in real life 63
Human papillomaviruses 53 and 66: clinical aspects and genetic analysis 63
HIV-1 dual/mixed tropic isolates show different genetic and phenotypic characteristics and response to maraviroc in vitro 63
Epidemiology and Resistance Profiles of Bacteria Isolated From Blood Samples in Septic Patients at Emergency Department Admission: A 6-Year Single Centre Retrospective Analysis From Northern Italy 63
An overview of SARS-CoV-2 variants circulating in the 2020-2022 period in Lombardy 62
BASELINE/EARLY PRESENCE OF KNOWN AND NOVEL RESISTANCE MUTATIONS IS ASSOCIATED WITH VIRAL FAILURE IN DIFFICULT-TO-TREAT PATIENTS TREATED WITH FIRST GENERATION PROTEASE INHIBITORS 62
Hepatitis C virus drug resistance associated substitutions and their clinical relevance: Update 2018 61
Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens 61
Clinical usefulness of HCV sequencing on clinical samples with different HCV-RNA levels 61
Dolutegravir Plus Lamivudine Two-Drug Regimen: Safety, Efficacy and Diagnostic Considerations for Its Use in Real-Life Clinical Practice-A Refined Approach in the COVID-19 Era 61
Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies 61
Study of genotypic and phenotypic HIV-1 dynamics of integrase mutations during raltegravir treatment: a refined analysis by ultra-deep 454 pyrosequencing 60
Rapid Detection and Quantification of Mycobacterium tuberculosis DNA in Paraffinized Samples by Droplet Digital PCR: A Preliminary Study 60
CHARACTERISTICS OF LAMIVUDINE RESISTANCE PROFILES IN HBV REVERSE TRANSCRIPTASE FROM A NATIONAL COLLABORATIVE STUDY OF HIV plus HBV INFECTED INDIVIDUALS ON LONG-EXPOSURE TO LAMIVUDINE INCLUDING REGIMENS 60
Italian expert panel consensus statements on two-drug antiretroviral regimens to treat naïve and virologically suppressed HIV-1 infected patients 59
Nasopharyngeal SARS-CoV-2 Load at Hospital Admission as a Predictor of Mortality 59
HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors 58
Biphasic kinetics of HCV-RNA decay and quasispecies evolution during DAA-treatment are associated with risk of virological failure 58
Polymorphism of the HLA system and weak antibody response to BNT162b2 mRNA vaccine 58
CLINICAL RELEVANCE OF BASELINE/EARLY DETECTION AND PERSISTENCE OF RESISTANT ASSOCIATED VARIANTS IN HCV-1 PATIENTS TREATED WITH PROTEASE-INHIBITORS ASSESSED BY ULTRA-DEEP SEQUENCING 57
Overlapping structure of hepatitis B virus (HBV) genome and immune selection pressure are critical forces modulating HBV evolution 57
Optimal cure rate by personalized HCV regimens in real-life: a proof-of-concept study 56
Distinct chromosomal mutation associated with cefiderocol resistance in Acinetobacter baumannii: a combined bioinformatics and mass spectrometry approach to unveil and validate the in vivo-acquired chemoresistance 56
Key genetic markers in the full-length HBsAg gene correlate with HBV-driven carcinogenesis by affecting HBsAg secretion and release 56
Quantitative SARS-CoV-2 subgenomic RNA as a surrogate marker for viral infectivity: Comparison between culture isolation and direct sgRNA quantification 56
Molecular analysis of hepatitis C virus infection in Bulgarian injecting drug users 55
Resistance to direct-acting antiviral agents: clinical utility and significance 55
HCV very late relapse following an atypical viral kinetics in a HIV patient treated for hepatitis C with direct-acting antivirals 55
High Burden of HBV-Infection and Atypical HBV Strains among HIV-infected Cameroonians 55
Exploring resistance pathways for first-generation NS3/4A protease inhibitors boceprevir and telaprevir using Bayesian network learning 55
The need for a European hepatitis C programme monitoring resistance to direct-acting antiviral agents in real life to eliminate hepatitis C 54
The use of human immunodeficiency virus resistance tests in clinical practice 54
Frontline Screening for SARS-CoV-2 Infection at Emergency Department Admission by Third Generation Rapid Antigen Test: Can We Spare RT-qPCR? 54
Two-drug regimens with dolutegravir plus rilpivirine or lamivudine in HIV-1 treatment-naïve, virologically-suppressed patients: Latest evidence from the literature on their efficacy and safety 54
HCV DIVERSITY AND FIBROSIS PROGRESSION: NS5A AND CORE VARIANTS CORRELATE WITH SEVERITY OF HCV RECURRENCE AFTER LIVER TRANSPLANTATION 53
Hepatitis C virus gene sequencing as a tool for precise genotyping in the era of new direct antiviral agents 53
Characteristic and prevalence of NS3, NS5A and NS5B resistance associated substitutions in DAA-naive and DAA-failed HCV-3 patients in Italy 52
Viral Respiratory Infections: New Tools for a Rapid Diagnosis 52
DIFFERENT PREVALENCE OF HCV RESISTANCE AND HCV QUANTIFICATION WITHIN BLOOD AND LIVER SAMPLES (TUMORAL AND NON TUMORAL TISSUES) OF HCC/TRANSPLANTED PATIENTS 51
KEY PATTERNS OF HBsAg MUTATIONS CORRELATE WITH MECHANISMS UNDERLYING LEVELS OF SERUM HBV DNA 51
Effective Rapid Diagnosis of Bacterial and Fungal Bloodstream Infections by T2 Magnetic Resonance Technology in the Pediatric Population 51
Intratype variations of HPV 31 and 58 in Italian women with abnormal cervical cytology 51
The genotypic false positive rate determined by V3 population sequencing can predict the burden of HIV-1 CXCR4-using species detected by pyrosequencing 51
Early detection of NS3-resistance in HCV patients with advanced disease treated with BOC/TVR-based therapy: analysis by population- and ultra-deep sequencing 50
Persistent positivity and fluctuations of SARS-CoV-2 RNA in clinically-recovered COVID-19 patients 50
KEY PATTERNS OF HBX AND PRE-S1/S2 MUTATIONS ARE INVOLVED IN MECHANISMS UNDERLYING HBV-INDUCED HEPATOCELLULAR CARCINOMA IN VIVO 49
KEY GENETIC SIGNATURES IN THE WHOLE pre-S1/Pre-S2/S GENE CORRELATE WITH HBV-INDUCED CARCINOGENESIS BY AFFECTING HBsAg SECRETION AND RELEASE 49
Prolongation of incubation time improves clinical diagnosis of Mycobacterium xenopi infection and allows susceptibility testing of mycobacterial strains against multiple antibiotics 49
High Incidence of sepsis caused by MDR bacteria in patients undergoing Percutaneous biliary drainage for the treatment of biliary obstruction 48
Snapshot on drug-resistance rate and profiles in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice 48
Increase in invasive group A streptococcal infections in Milan, Italy: a genomic and clinical characterization 48
HCV-RNA quantification in liver bioptic samples and extrahepatic compartments, using the abbott RealTime HCV assay 48
Performance evaluation of a new on-demand molecular test for the rapid identification of severe acute respiratory syndrome coronavirus 2 in pediatric and adult patients 47
CORRELATION OF EARLY DETECTION OF HCV NS3-RESISTANCE AND VIROLOGICAL FAILURE IN PATIENTS TREATED WITH TRIPLE THERAPY INCLUDING TELAPREVIR OR BOCEPREVIR 46
HCV GENOTYPES HAVE DIFFERENT GENETIC BARRIERS IN THE GENERATION OF RESISTANCE MUTATIONS TO PROTEASE INHIBITORS IN ADVANCED CLINICAL DEVELOPMENT 46
Fast and deep early HCV-RNA decay is accompanied by fast aminotransferases normalization values in cirrhotic HCV-1 patients treated with paritaprevir/r-ombitasvir and dasabuvir with ribavirin: a potential role of baseline major resistance mutations 46
Totale 7.018
Salva come PNG Salva come JPEG
Categoria #
all - tutte 51.053
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 51.053
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022104 0 1 0 3 1 0 1 2 6 4 77 9
2022/20231.183 149 15 97 120 79 103 0 129 220 101 161 9
2023/20241.148 77 121 258 82 45 175 70 64 16 36 98 106
2024/20251.508 27 4 6 38 28 181 64 75 289 379 183 234
2025/20264.885 585 504 761 388 174 265 1.241 168 211 241 204 143
Totale 8.851